Revolution Medicines, Inc. (RVMD)

US — Healthcare Sector

Peers: BPMC SANA KYMR GLUE TCRR BDTX BCEL PASG AKRO RNA PTGX STOK FIXX CCCC AGIO NRIX

Automate Your Wheel Strategy on RVMD

With Tiblio's Option Bot, you can configure your own wheel strategy including RVMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol RVMD
Rev/Share 1.3904
Book/Share 11.0454
PB 3.6151
Debt/Equity 0.0646
CurrentRatio 13.459
ROIC -0.356

MktCap 7437681240.0
FreeCF/Share -3.1981
PFCF -12.3607
PE -10.7708
Debt/Assets 0.0568
DivYield 0
ROE -0.3706

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 2
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

RVMD
Published: June 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Revolution Medicines is advancing a groundbreaking pan-RAS inhibitor pipeline, targeting historically undruggable mutations in tough cancers like pancreatic and lung. Early clinical data for daraxonrasib and zoldonrasib show strong efficacy and tolerability, sparking excitement among oncologists and analysts alike. Despite a robust cash position, RVMD's high burn rate and lofty valuation increase risk and sensitivity to setbacks, making entry timing challenging.

image for news Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History

Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript

RVMD
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Ryan Asay - Senior Vice President-Corporate Affairs Mark Goldsmith - Chairman and Chief Executive Officer Steve Kelsey - President-Research and Development Wei Lin - Chief Medical Officer Jack Anders - Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Marc Frahm - TD Cowen Eric Joseph - J.P. Morgan Jonathan Chang - Leerink Partners Kelly Shi - Jefferies Ellie Merle - UBS Operator Good day, and thank you for standing by.

image for news Revolution Medicines, Inc. (RVMD) Q1 2025 Earnings Call Transcript

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

RVMD
Published: April 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer Zoldonrasib, a RAS(ON) G12D-selective inhibitor, demonstrated acceptable tolerability and encouraging initial antitumor activity in patients with previously treated KRAS G12D mutant non-small cell lung cancer

image for news Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

RVMD
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancer Company anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025 Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif.

image for news Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?

RVMD
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

image for news Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?

About Revolution Medicines, Inc. (RVMD)

IPO Date 2020-02-13
Website https://www.revmed.com
Industry Biotechnology
CEO Dr. Mark A. Goldsmith Ph.D.
Employees 616

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.